|5.22||-0.10 / -1.88%|
Data as of 3:59pm ET
|5.22||0.00 / 0.00%|
The 2 analysts offering 12-month price forecasts for Progenics Pharmaceuticals Inc have a median target of 9.50, with a high estimate of 11.00 and a low estimate of 8.00. The median estimate represents a +81.99% increase from the last price of 5.22.
The current consensus among 3 polled investment analysts is to Buy stock in Progenics Pharmaceuticals Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.